CoChat

Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity

Suzuki, Eiji, Kapoor, Veena, Jassar, Arminder Singh, Kaiser, Larry R., Albelda, Steven M. · 2005 · Clinical Cancer Research

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

PURPOSE: Myeloid suppressor (Gr-1(+)/CD11b(+)) cells accumulate in the spleens of tumor-bearing mice where they contribute to immunosuppression by inhibiting the function of CD8(+) T cells and by promoting tumor angiogenesis. Elimination of these myeloid suppressor cells may thus significantly improve antitumor responses and enhance effects of cancer immunotherapy, although to date few practical options exist. EXPERIMENTAL DESIGN: The effect of the chemotherapy drug gemcitabine on the number of (Gr-1(+)/CD11b(+)) cells in the spleens of animals bearing large tumors derived from five cancer lines grown in both C57Bl/6 and BALB/c mice was analyzed. Suppressive activity of splenocytes from gemcitabine-treated and control animals was measured in natural killer (NK) cell lysis and Winn assays. The impact of myeloid suppressor cell activity was determined in an immunogene therapy model using an adenovirus expressing IFN-beta. RESULTS: This study shows that the chemotherapeutic drug gemcitabine, given at a dose similar to the equivalent dose used in patients, was able to dramatically and specifically reduce the number of myeloid suppressor cells found in the spleens of animals bearing large tumors with no significant reductions in CD4(+) T cells, CD8(+) T cells, NK cells, macrophages, or B cells. The loss of myeloid suppressor cells was accompanied by an increase in the antitumor activity of CD8(+) T cells and activated NK cells. Combining gemcitabine with cytokine immunogene therapy using IFN-beta markedly enhanced antitumor efficacy. CONCLUSIONS: These results suggest that gemcitabine may be a practical strategy for the reduction of myeloid suppressor cells and should be evaluated in conjunction with a variety of immunotherapy approaches.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-05-0883

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 33 references

Cited by

See all 1,054

Metadata

Authors
Suzuki, E., Kapoor, V., Jassar, A. S., Kaiser, L. R., & Albelda, S. M.
Affiliations
  • University of Pennsylvania (US)
  • Authors' Affiliation: Thoracic Oncology Research Laboratory, University of Pennsylvania, Philadelphia, Pennsylvania
Venue
Clinical Cancer Research
Published
2005-09-15
Volume
11
Issue
18
Pages
6713-6721
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2111415894
Cited by
1,054
References
33
Citations by year
2026: 19 · 2025: 33 · 2024: 41 · 2023: 42 · 2022: 50 · 2021: 59 · 2020: 70 · 2019: 52 · 2018: 59 · 2017: 72 · 2016: 76 · 2015: 78 · 2014: 66 · 2013: 77 · 2012: 72
FWCI
6.09
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Cancer Institute (P01CA066726)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
gemcitabine, myeloid-derived suppressor cells, spleen, tumor immunosuppression, antitumor immunity, CD8+ T cells, natural killer cells, immunogene therapy, interferon-beta, tumor-bearing mice, chemoimmunotherapy
MeSH terms
Gemcitabine, Adenoviridae, Analysis of Variance, Animals, Antineoplastic Agents, B-Lymphocytes, Cell Line, Deoxycytidine, Female, Flow Cytometry, Genetic Vectors, Immunotherapy, Killer Cells, Natural, Mice, Inbred BALB C, Mice, Inbred C57BL, Necrosis, Neoplasms, Experimental, Spleen, T-Lymphocytes, Cytotoxic, Time Factors, Genetic Therapy, CD4-Positive T-Lymphocytes, Interferon-beta, Apoptosis, CD8-Positive T-Lymphocytes, Lymphocyte Count, Receptors, Chemokine, CD11b Antigen, Cell Line, Tumor, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-05-0883
The paper
Suzuki, E., Kapoor, V., Jassar, A. S., Kaiser, L. R., & Albelda, S. M. (2005). Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-05-0883

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.